Researchers Identified Protein Driving Lung Cancer Growth
A new study has linked the TRIM46 protein to the progression of lung adenocarcinoma and resistance to chemotherapy.
Updated on Sept. 22, 2026 in Cancer
Scientists have discovered that the TRIM46 protein plays a central role in driving the progression of lung adenocarcinoma. The research reveals how this protein stabilizes specific cellular components to promote tumor survival and chemoresistance.
Why it matters
The findings identify the ZNF143-TRIM46-PRDX1 signaling axis as a potential new therapeutic target. Addressing this pathway could eventually improve treatment outcomes for patients facing resistance to cisplatin chemotherapy.
The study identified lysine109 as the specific site where PRDX1 SUMOylation occurs. High levels of TRIM46 correlate with poor patient prognosis compared to those with lower expression levels.
The players
TRIM46
This protein acts as a key driver of malignancy in lung adenocarcinoma by stabilizing essential cellular proteins.
PRDX1
This protein is stabilized through SUMOylation to suppress ferroptosis and support tumor cell survival.
ZNF143
This transcription factor serves as the upstream regulator responsible for the overexpression of TRIM46.
The details
TRIM46 recruits the enzyme UBC9 to catalyze the SUMOylation of PRDX1 at the lysine109 site, which prevents its degradation. By stabilizing PRDX1, the protein suppresses lipid peroxidation and ferroptosis, ultimately allowing cancer cells to survive and proliferate despite exposure to cisplatin.
Timeline
The study was published on September 22, 2026.
The Big Picture
This discovery follows the pattern set by the NCI-MATCH clinical trial program, which seeks to match targeted therapies to specific genetic alterations found in tumors. By identifying a new signaling axis, the research provides a target for future precision medicine strategies.
While this study provides a foundation for new research, it does not currently change existing treatment protocols for lung cancer patients. Scientists will need to translate these laboratory findings into clinical trials to determine future options for overcoming chemoresistance.
The takeaway
Understanding how cancer cells resist chemotherapy at the molecular level is vital for developing more effective drug combinations. Patients should consult with their oncologists regarding clinical trials that target specific biomarkers identified by ongoing research.
Further reading
Learn more about the latest developments in Cancer research on our dedicated hub.
More information
Review the detailed findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
